PDCD1 and cancer: Administration of antibodies that bind PD-1 on T cells or PD-L1 (expressed by malignant tumor cells or antigen-presenting cells) inhibits interaction with PD-1 on T cells, thereby inhibiting inhibitory signaling to T cells, maintaining the activation of CD8+ cytotoxic T cells, and exerting antiviral and antitumor effects [11].